Alpha 2.0
Login Register
» Authors » Akito Hata

Akito Hata

Explore the profile of Akito Hata including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 133
Citations 1363
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Chemistry
Top 10 Co-Authors
Nobuyuki Katakami
Shiro Fujita
Reiko Kaji
Nobuyuki Yamamoto
Katsuhiro Masago
Keisuke Tomii
Yukihiro Imai
Jumpei Takeshita
Motohiro Tamiya
Chiyuki Okuda
Published In
J Thorac Oncol
Lung Cancer
Anticancer Res
JTO Clin Res Rep
Gan To Kagaku Ryoho
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
Tanzawa S, Yoshioka H, Misumi T, Miyauchi E, Ninomiya K, Murata Y, et al.
Ther Adv Med Oncol . 2025 Feb; 17:17588359251318850. PMID: 39957806
Background: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. Objective: We aimed to evaluate the clinical characteristics...
2.
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning
Fujimoto D, Shibaki R, Kimura K, Haratani K, Tamiya M, Kijima T, et al.
Lung Cancer . 2025 Jan; 199:108079. PMID: 39787635
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC...
3.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study
Sugisaka J, Fujimoto D, Tamiya M, Hata A, Matsumoto H, Yokoyama T, et al.
Lung Cancer . 2024 Dec; 199:108056. PMID: 39674045
Background: Chemoimmunotherapy is the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC); however, its real-world long-term outcomes associated with patient backgrounds are still unclear. We explored this association using...
4.
Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study
Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, et al.
Lung Cancer . 2024 Oct; 197:107988. PMID: 39393258
Introduction: Many clinical studies showed a synergy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) and vascular endothelial growth factor inhibitors. We hypothesized afatinib plus bevacizumab exerts clinical potency...
5.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
Shibaki R, Fujimoto D, Miyauchi E, Tsukita Y, Nakachi I, Arai D, et al.
Lung Cancer . 2024 Sep; 196:107958. PMID: 39312871
Objectives: Certain guidelines recommend caution when administering immunotherapy in patients with pre-existing interstitial lung disease (ILD) owing to the high incidence of pneumonitis induced by anti-cancer therapy. A prospective clinical...
6.
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL
Yagishita S, Goto Y, Nishio M, Akamatsu H, Hayashi H, Miura S, et al.
JTO Clin Res Rep . 2024 Aug; 5(7):100683. PMID: 39091595
Introduction: This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC and explored the relationship between PK parameters, effectiveness,...
7.
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
Hata A, Iwasawa S, Sasaki Y, Tajima K, Chiba Y
Adv Ther . 2024 Jul; 41(9):3520-3538. PMID: 38990434
Introduction: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) combination therapy is a standard of care for advanced non-squamous non-small cell lung cancer (NSQ-NSCLC); however, the lack of safety data limits its...
8.
Cystine and theanine for chemoradiotherapy-induced esophagitis in non-small cell lung cancer: a prospective observational study
Kariya M, Yamamoto K, Kawamura A, Tanizaki S, Ueda K, Sai K, et al.
Support Care Cancer . 2024 Jun; 32(6):400. PMID: 38829486
Purpose: Although several potential radioprotectants have been explored, radiation esophagitis is still difficult to control. Further development of supportive therapies is required. Our purpose was to investigate the efficacy and...
9.
Quantification of cerebrospinal fluid tumor DNA in lung cancer patients with suspected leptomeningeal carcinomatosis
Azad T, Nanjo S, Jin M, Chabon J, Kurtz D, Chaudhuri A, et al.
NPJ Precis Oncol . 2024 May; 8(1):121. PMID: 38806586
Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81...
10.
Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab
Kachi S, Sumitomo S, Oka H, Hata A, Ohmura K
Front Immunol . 2024 May; 15:1400097. PMID: 38799449
This report describes the case of a 48-year-old woman who presented with sternoclavicular joint arthritis after administration of an immune checkpoint inhibitor (ICI), durvalumab, for small cell lung carcinoma. The...